U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C31H38N2O6
Molecular Weight 534.6432
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAGLUTRIL

SMILES

CCOC(=O)[C@H](CCC1=CC=CC=C1)CC2(CCCC2)C(=O)N[C@H]3CCC4=CC=CC=C4N(CC(O)=O)C3=O

InChI

InChIKey=XMQODGUTLZXUGZ-RPBOFIJWSA-N
InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1

HIDE SMILES / InChI

Molecular Formula C31H38N2O6
Molecular Weight 534.6432
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/25131455 http://adisinsight.springer.com/drugs/800010577

The new chemical entity KC12615 is a potent f neutral endopeptidase inhibitor with additional endothelin-converting enzyme (ECE)–inhibitory activity.2 KC12615 is the hydrolyzed form of the oral prodrug SLV306 (daglutril). In plasma, the compound increases natriuretic peptide levels and prevents the formation of endothelin-1 by inhibiting the degradation of its precursor, big endothelin. It is investigated for use/treatment in congestive heart failure and hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.2 nM [IC50]
1.5 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources: Page: p.238
unhealthy
n = 19
Health Status: unhealthy
Condition: congestive heart failure
Sex: M+F
Food Status: UNKNOWN
Population Size: 19
Sources: Page: p.238
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

150, 300, 600 mg Once Daily or 150-300 mg Twice Daily
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:34:19 GMT 2023
Edited
by admin
on Fri Dec 15 16:34:19 GMT 2023
Record UNII
KKV299446X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DAGLUTRIL
INN  
INN  
Official Name English
SLV306
Code English
SLV-306
Code English
((3S)-3-(1-((2R)-2-ETHOXYCARBONYL-4-PHENYLBUTYL)CYCLOPENTANECARBOXAMIDO)-2-OXO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-1-YL)ACETIC ACID
Systematic Name English
daglutril [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C783
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
Code System Code Type Description
CAS
182821-27-8
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
PUBCHEM
3038505
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
DRUG BANK
DB05796
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107738
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
INN
8351
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
NCI_THESAURUS
C73039
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
SMS_ID
100000175036
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
FDA UNII
KKV299446X
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID60171341
Created by admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY